SML2861
FIT-039
≥98% (HPLC)
Synonym(s):
FIT 039, FIT039, N-(5-Fluoro-2-(piperidin-1-yl)phenyl)pyridine-4-carbothioamide, N-[5-Fluoro-2-(1-piperidinyl)phenyl]-4-pyridinecarbothioamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H18FN3S
CAS Number:
Molecular Weight:
315.41
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
Fc1cc(c(cc1)N3CCCCC3)NC(=S)c2ccncc2
InChI key
VRKZHYSJZOUICG-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells. FIT-039 ointment inhibits formation of skin legion in a mice HSV-1 infection model.
potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor; antiviral agent
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Eriko Sumi et al.
Clinical drug investigation, 39(1), 55-61 (2018-10-05)
Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an
Makoto Yamamoto et al.
The Journal of clinical investigation, 124(8), 3479-3488 (2014-07-09)
A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk. Here, we explored the use of compounds that inhibit or interfere with the action of essential host
Masahiko Ajiro et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(18), 4518-4528 (2018-05-02)
Purpose: Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide. The purpose of this study is to assess the therapeutic effect of the newly developed cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on cervical neoplasia induced
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service